Concepedia

Jakub Żołnierek

JŻ

15

Publications

3.8K

Citations

13

H-Index

2008

Active since

Affiliations

The Maria Sklodowska-Curie National Research Institute of Oncology(Current)

Memorial Sloan Kettering Cancer Center

Gdańsk Medical University

Wojskowy Instytut Medycyny Lotniczej

Merck & Co., Inc., Rahway, NJ, USA (United States)

Jakub Żołnierek is an author at The Maria Sklodowska-Curie National Research Institute of Oncology specializing in oncology, medicine, and urology.

ORCID

Top concepts

Publications per year

2008–2023

15

Publications

15

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Mauricio Burotto et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Robert J. Motzer, Thomas E. Hutson, Hilary Glen et al. · The Lancet Oncology · 2015 · 929 citations

, , +4

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez et al. · The Lancet Oncology · 2023 · 521 citations

, , +8

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

Robert J. Motzer, Camillo Porta, Nicholas J. Vogelzang et al. · The Lancet Oncology · 2014 · 262 citations · Full text

, , +7

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

Arkadiusz Z. Dudek, Jakub Żołnierek, Anu Dham et al. · Cancer · 2008 · 188 citations

Rows per page

1–5 of 15